• The Role of the Statistical Programmer is Evolving: Here’s How It’s Changing and What That Means for Pharmaceutical Companies

    Bio-IT World | For decades, the role of statistical programmers in drug development was clearly defined. They were responsible for producing validated tables, listings, and figures from clinical trial data, most often using statistical analysis systems, within structured workflows for regulatory submissions. That model is now under pressure.

    Feb 6, 2026

  • PacBio Sells Their Short-Read IP to Illumina

    Bio-IT World | Yesterday, PacBio announced the completion of the sale of short-read DNA sequencing technology to Illumina. PacBio received $48.1 million in net cash proceeds from the transaction. The sale closed on January 30, 2026.

    Feb 3, 2026

  • Unlocking the Dangers of Disrupted Sleep

    Bio-IT World | It has been known for some time now that for people with irregular sleep patterns, including shift workers and frequent travelers across time zones, disruptions to the body’s circadian rhythm can be deadly. The dangers have notably included heightened risk of aggressive breast cancer.

    Feb 3, 2026

  • Eli Lilly Gears Up for a Busy Year with a Diversified Pipeline

    Bio-IT World | Earlier this month at the J.P. Morgan Healthcare Conference, Eli Lilly Chairman and CEO David Ricks spoke at a fireside chat and presented what the company has planned for 2026, which also marks its 150th anniversary. This year is expected to be a productive one in terms of clinical trial activity, wider availability of medicines, and expansion into new therapeutic areas.

    Jan 29, 2026

  • Follow the Money: Helicon Peptide Development, Next-Gen Obesity Metabolic Disease Therapies, Cell Stress Sensing Platform

    Bio-IT World | Parabilis Medicines will continue the clinical development of FOG-001 (zolucatetide), the company’s lead investigational Helicon peptide; Alveus Therapeutics will advance into Phase 2 clinical development of ALV-100, the company’s lead program; Soley Therapeutics plans to advance its proprietary cell stress sensing platform; and more.

    Jan 28, 2026

  • BigHat, Revvity Collaborate with Eli Lilly, Immunai Signs Agreement with Bristol Myers Squibb, SandboxAQ Launches New AI Model

    Bio-IT World | BigHat Biosciences and Revvity have entered collaborations with Eli Lilly and Company; Immunai has signed an agreement with Bristol Myers Squibb; SandboxAQ launches a new AI model; and more.

    Jan 27, 2026

  • Dealmakers Predict Banner Year as Biopharma M&A Momentum Builds

    Bio-IT World | The mood at this year's J.P. Morgan Healthcare Conference signals a dramatic shift for biopharma dealmaking, with industry leaders projecting 2026 could eclipse last year's surging merger and acquisition activity. During an Endpoints News panel discussion, senior executives from AbbVie, Amgen, and Merck expressed confidence that favorable market conditions and breakthrough science are converging to create what one panelist called "a renaissance moment" for the sector.

    Jan 23, 2026